20:02 , Nov 2, 2018 |  BC Week In Review  |  Company News

Glenmark opens first U.S. manufacturing site

Indian company Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) opened its first U.S. manufacturing site in Monroe, N.C. The company invested $100 million in the site, which has 168 employees and will produce fixed-dose pharmaceutical formulations. Glenmark...
18:21 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Harbour BioMed raises $85M series B on heels of cancer deals

Immuno-oncology company Harbour BioMed (Shanghai, China) raised $85 million in a series B round led by GIC. New investors China Life Private Equity Investment Company and Vertex Ventures also participated as did existing investors AdvanTech...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
19:02 , Aug 30, 2018 |  BioCentury  |  Finance

Building a deeper Harbour

With an $85 million B round in hand, Harbour BioMed plans to advance newly in-licensed clinical programs while simultaneously building its pipeline through its internal platform and co-discovery deals. Singapore sovereign wealth fund GIC led...
22:31 , Aug 27, 2018 |  BC Extra  |  Financial News

Harbour BioMed raises $85M on heels of cancer deals

Immuno-oncology company Harbour BioMed (Shanghai, China) raised $85 million in a series B round led by GIC. New investors China Life Private Equity Investment Company and Vertex Ventures also participated as did existing investors AdvanTech...
21:12 , Aug 20, 2018 |  BC Extra  |  Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
18:43 , Aug 10, 2018 |  BC Week In Review  |  Company News

India's Glenmark grants China's Harbour rights to bispecific mAb for cancer

Indian company Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize GBR 1302 in Greater China, including Hong Kong and Macau, and Taiwan. The deal is Glenmark’s first with...
21:48 , Aug 6, 2018 |  BC Extra  |  Company News

India's Glenmark grants China's Harbour rights to bispecific mAb for cancer

Indian company Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize GBR 1302 in Greater China. According to BioCentury’s BCIQ database, the deal is Glenmark’s first with a Chinese...
22:41 , Jul 20, 2018 |  BC Extra  |  Company News

Management tracks: Merck KGaA, Aeglea

Merck KGaA (Xetra:MRK) hired Maria Rivas as SVP, head of global medical affairs. She was SVP, head of medical affairs at Merck & Co. Inc. (NYSE:MRK). Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said interim...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...